Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease
Articolo
Data di Pubblicazione:
2016
Citazione:
Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease / R. Cilia, R. Benfante, R. Asselta, L. Marabini, E. Cereda, C. Siri, G. Pezzoli, S. Goldwurm, D. Fornasari. - In: PARKINSONISM & RELATED DISORDERS. - ISSN 1353-8020. - 29(2016 Aug), pp. 96-103. [10.1016/j.parkreldis.2016.05.017]
Abstract:
Background Impulse control disorders and compulsive medication intake may occur in a minority of patients with Parkinson's disease (PD). We hypothesize that genetic polymorphisms associated with addiction in the general population may increase the risk for addictive behaviors also in PD. Methods Sixteen polymorphisms in candidate genes belonging to five neurotransmitter systems (dopaminergic, catecholaminergic, serotonergic, glutamatergic, opioidergic) and the BDNF were screened in 154 PD patients with addictive behaviors and 288 PD control subjects. Multivariate analysis investigated clinical and genetic predictors of outcome (remission vs. persistence/relapse) after 1 year and at the last follow-up (5.1 ± 2.5 years). Results Addictive behaviors were associated with tryptophan hydroxylase type 2 (TPH2) and dopamine transporter gene variants. A subsequent analysis within the group of cases showed a robust association between TPH2 genotype and the severity of addictive behaviors, which survived Bonferroni correction for multiple testing. At multivariate analysis, TPH2 genotype resulted the strongest predictor of no remission at the last follow-up (OR[95%CI], 7.4[3.27–16.78] and 13.2[3.89–44.98] in heterozygous and homozygous carriers, respectively, p < 0.001). The extent of medication dose reduction was not a predictor. TPH2 haplotype analysis confirmed the association with more severe symptoms and lower remission rates in the short- and the long-term (p < 0.005 for all analyses). Conclusion The serotonergic system is likely to be involved in the pathophysiology of addictive behaviors in PD, modulating the severity of symptoms and the rate of remission at follow-up. If confirmed in larger independent cohorts, TPH2 genotype may become a useful biomarker for the identification of at-risk individuals.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
addiction; genetics; impulse control disorders; parkinson disease; serotonin; neurology; geriatrics and gerontology; neurology (clinical)
Elenco autori:
R. Cilia, R. Benfante, R. Asselta, L. Marabini, E. Cereda, C. Siri, G. Pezzoli, S. Goldwurm, D. Fornasari
Link alla scheda completa: